Original ArticlesPreliminary Evidence for Heterogeneity of Beliefs About Auditory Verbal Hallucinations IntentZanello, Adriano MA∗; Dugré, Jules R. MSc†,‡Author Information ∗Department of Mental Health and Psychiatry, University Hospitals of Geneva, Geneva, Switzerland †Centre de Recherche de l'Institut Universitaire en Santé Mentale de Montréal ‡Département de Psychiatrie, Faculté de Médecine, Université de Montréal, Pavillon Roger-Gaudry, Montreal, Canada. Send reprint requests to Adriano Zanello, MA, Department of Mental Health and Psychiatry, University Hospitals of Geneva, Belle-Idée, Unité des Tilleuls, Ch. du Petit-Bel-Air 2, 1226 Thônex, Switzerland. E-mail: [email protected]. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.jonmd.com). The Journal of Nervous and Mental Disease: December 2021 - Volume 209 - Issue 12 - p 872-878 doi: 10.1097/NMD.0000000000001391 Buy SDC Metrics AbstractIn Brief Perceptions of patient's auditory verbal hallucinations (AVHs), commonly termed voices, have important impacts on their everyday lives. Despite research emphasizing the consequences of malevolent voices, preliminary results suggest that beliefs about voices may not be mutually exclusive. As such, we aimed to characterize the heterogeneity of beliefs about AVHs and describe their clinical correlates. We recruited 78 patients referred to a Voices group therapy for refractory and distressing voices. Based on the Revised Beliefs About Voices Questionnaire, clustering analysis yielded four subgroups of patients with distinct pattern of beliefs about AVHs. These subgroups differed significantly in terms of affective disturbances, engagement, and resistance to their voices. Furthermore, no significant changes in beliefs about voices were observed after 6 weeks. Results of the current study suggest that the heterogeneity regarding the beliefs about AVHs should be targeted in treatment to reduce their associated negative outcomes. Supplemental digital content is available. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.